O	0	1	A
O	2	12	randomized
O	13	18	phase
O	19	21	II
O	22	27	trial
O	28	37	comparing
B-intervention	38	50	preoperative
I-intervention	51	55	plus
I-intervention	56	69	perioperative
I-intervention	70	82	chemotherapy
O	83	87	with
O	88	100	preoperative
O	101	113	chemotherapy
O	114	116	in
O	117	125	patients
O	126	130	with
O	131	138	locally
O	139	147	advanced
O	148	154	breast
O	155	161	cancer
O	161	162	.

O	163	166	The
O	167	170	aim
O	171	173	of
O	174	178	this
O	179	184	study
O	185	188	was
O	189	191	to
O	192	203	investigate
O	204	206	in
O	207	208	a
O	209	219	randomized
O	220	225	trial
O	226	229	the
O	230	238	activity
O	239	241	of
O	242	255	perioperative
O	256	268	chemotherapy
O	269	271	in
B-eligibility	272	280	patients
I-eligibility	281	288	treated
I-eligibility	289	293	with
I-eligibility	294	306	preoperative
I-eligibility	307	319	chemotherapy
I-eligibility	320	323	for
I-eligibility	324	331	locally
I-eligibility	332	340	advanced
I-eligibility	341	347	breast
I-eligibility	348	354	cancer
O	355	358	and
O	359	361	to
O	362	369	compare
O	370	372	it
O	373	377	with
O	378	381	the
O	382	394	preoperative
O	395	407	chemotherapy
O	408	413	alone
O	413	414	.

O	415	423	Patients
O	424	428	with
O	429	432	cT2
O	432	433	-
O	433	434	3
O	435	437	N0
O	437	438	-
O	438	439	2
O	440	442	M0
O	443	457	histologically
O	458	464	proven
O	465	471	breast
O	472	478	cancer
O	478	479	,
O	480	484	with
O	485	493	estrogen
O	494	503	receptors
O	504	507	and
O	508	520	progesterone
O	521	530	receptors
O	531	533	in
O	534	538	less
O	539	543	than
O	544	546	20
O	546	547	%
O	548	550	of
O	551	556	cells
O	556	557	,
O	558	560	or
O	561	565	with
O	566	573	absence
O	574	576	of
O	577	589	progesterone
O	590	599	receptors
O	599	600	,
O	601	609	received
O	610	620	epirubicin
O	621	623	25
O	624	626	mg
O	626	627	/
O	627	628	m
O	629	633	days
O	634	635	1
O	636	639	and
O	640	641	2
O	641	642	,
O	643	652	cisplatin
O	653	655	60
O	656	658	mg
O	658	659	/
O	659	660	m
O	661	664	day
O	665	666	1
O	666	667	,
O	668	671	and
O	672	684	fluorouracil
O	685	688	200
O	689	691	mg
O	691	692	/
O	692	693	m
O	694	699	daily
O	700	702	as
O	703	713	continuous
O	714	722	infusion
O	722	723	.

O	724	734	Responding
O	735	743	patients
O	744	748	were
O	749	759	randomized
O	760	762	to
O	763	771	continue
O	772	784	fluorouracil
O	785	790	until
O	791	792	2
O	793	798	weeks
O	799	804	after
O	805	812	surgery
O	813	814	(
O	814	827	perioperative
O	828	840	chemotherapy
O	840	841	)
O	842	844	or
O	845	847	to
O	848	852	stop
O	853	865	fluorouracil
O	866	867	1
O	868	872	week
O	873	879	before
O	880	887	surgery
O	887	888	.

B-total-participants	889	894	Fifty
I-total-participants	894	895	-
I-total-participants	895	900	eight
O	901	909	patients
O	910	919	completed
O	920	923	six
O	924	931	courses
O	932	934	of
O	935	945	epirubicin
O	945	946	,
O	947	956	cisplatin
O	957	960	and
O	961	973	fluorouracil
O	973	974	,
O	975	978	and
O	979	983	were
O	984	994	randomized
O	995	997	to
O	998	1011	perioperative
O	1012	1024	chemotherapy
O	1025	1026	(
B-intervention-participants	1026	1028	29
O	1029	1037	patients
O	1037	1038	)
O	1039	1041	or
O	1042	1044	to
B-control	1045	1052	control
O	1053	1054	(
B-control-participants	1054	1056	29
O	1057	1065	patients
O	1065	1066	)
O	1066	1067	.

O	1068	1071	The
B-outcome	1072	1078	median
I-outcome	1079	1081	Ki
I-outcome	1081	1082	-
I-outcome	1082	1084	67
I-outcome	1085	1090	index
O	1091	1099	remained
O	1100	1106	stable
O	1107	1108	(
O	1108	1110	32
O	1110	1111	-
O	1111	1113	27
O	1113	1114	.
O	1114	1115	5
O	1115	1116	%
O	1116	1117	)
O	1118	1120	in
O	1121	1124	the
O	1125	1138	perioperative
O	1139	1151	chemotherapy
O	1152	1155	arm
O	1156	1157	(
O	1157	1158	P
O	1158	1159	=
O	1159	1160	0
O	1160	1161	.
O	1161	1162	3
O	1162	1163	)
O	1164	1167	and
O	1168	1177	decreased
O	1178	1182	from
O	1183	1185	55
O	1186	1188	to
O	1189	1191	22
O	1191	1192	.
O	1192	1193	5
O	1193	1194	%
O	1195	1197	in
O	1198	1201	the
O	1202	1209	control
O	1210	1213	arm
O	1214	1215	(
O	1215	1216	P
O	1216	1217	=
O	1217	1218	0
O	1218	1219	.
O	1219	1221	01
O	1221	1222	)
O	1222	1223	.

O	1224	1227	The
B-outcome	1228	1232	rate
I-outcome	1233	1235	of
I-outcome	1236	1248	pathological
I-outcome	1249	1257	complete
I-outcome	1258	1267	remission
O	1268	1271	was
B-iv-bin-percent	1272	1274	41
I-iv-bin-percent	1274	1275	%
O	1276	1278	in
O	1279	1283	both
O	1284	1288	arms
O	1289	1290	(
O	1290	1291	P
O	1291	1292	=
O	1292	1293	1
O	1293	1294	.
O	1294	1295	0
O	1295	1296	)
O	1296	1297	.

O	1298	1300	No
O	1301	1312	significant
O	1313	1323	difference
O	1324	1326	in
O	1327	1332	terms
O	1333	1335	of
B-outcome	1336	1343	disease
I-outcome	1343	1344	-
I-outcome	1344	1348	free
I-outcome	1349	1357	survival
I-outcome	1358	1361	and
I-outcome	1362	1369	overall
I-outcome	1370	1378	survival
O	1379	1382	was
O	1383	1391	observed
O	1392	1399	between
O	1400	1403	the
O	1404	1407	two
O	1408	1412	arms
O	1412	1413	.

O	1414	1427	Perioperative
O	1428	1440	chemotherapy
O	1441	1447	failed
O	1448	1450	to
O	1451	1455	show
O	1456	1458	an
O	1459	1467	increase
O	1468	1470	in
O	1471	1474	the
O	1475	1487	pathological
O	1488	1496	complete
O	1497	1506	remission
O	1507	1511	rate
O	1511	1512	.

O	1513	1514	A
O	1515	1525	biological
O	1526	1532	effect
O	1533	1535	on
O	1536	1538	Ki
O	1538	1539	-
O	1539	1541	67
O	1542	1552	expression
O	1553	1556	was
O	1557	1569	demonstrated
O	1569	1570	.
